BioLineRx Ltd (BLRX)

BioLineRx Ltd (BLRX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $11.7M; returns 1 day -1.1%, 1 week +1.5%, 1 year -44.3%.

BioLineRx Ltd. is a biopharmaceutical company based in Israel that focuses on developing and commercializing therapies for oncology and rare diseases. Its first approved product is APHEXDA® (motixafortide), indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. APHEXDA® is being commercialized by Ayrmid Ltd.

Groups BLRX belongs to

• Biotechnology
• Israel Companies
• Israel
• Oncology
• Biopharmaceutical
• Rare Diseases
• Commercial Stage Biotech
• Healthcare
• Life Sciences
• Hematologic Malignancies
• Royalty Streams
• Autologous Cell Therapy

BLRX financial model: income statement, cash flow and balance sheet